Table 1.
Competition SPR and antiviral inhibition efficacies of UM-24, KR-41 and KR-42 peptides.
| Peptide | SPR[a] | EC50 (μM)[a] | |
|---|---|---|---|
| sCD4 | m17b | ||
| IC50 (nM) | |||
| UM-24 | 45.0 ± 0.4 | 71.5 ± 0.2 | 6.7 ± 1 |
| KR-41 | 30.0 ± 0.4 | 50.8 ± 0.1 | 14.0 ± 2 |
| KR-42 | 118.7 ± 0.6 | 207.8 ± 0.5 | 29.0 ± 4 |
[a]
Each data point shown is the average of triplicate experiments, and the data are reported as the mean with standard deviation. SPR IC50 values were determined using competition SPR. Antiviral IC50 values were obtained through a single-round infection assay and expressed as relative infection versus untreated (100%).